Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...
for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly ...
Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2. The FDA approved ...
About Macular Telangiectasia Type 2 (MacTel) Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback